

## Through the Lens: Cryoglobulinemia

A 51-year-old lady presented with episodic discoloration of lower extremities associated with severe pain of 2 years' duration. She was a nonsmoker, nondiabetic, and normotensive. On examination, she had gangrene involving the left great toe [Figure 1]. Evaluation revealed hepatitis C virus (HCV) RNA copies – 1.4 million copies/mL, genotype – 3, cryoglobulins – present, rheumatoid factor – positive and thrombocytopenia. Color Doppler involving lower limb vessels and two-dimensional echocardiography were normal. Histopathology of the skin showed fibrinoid deposits and thrombus formation in dermal capillaries without active vasculitis. Diagnosis of HCV-associated cryoglobulinemic vasculitis was made. She was treated with tablet sofosbuvir 400 mg and daclatasvir 60 mg once a day along with tablet prednisolone 40 mg once a day. She responded favorably to treatment, and review at 3 months showed resolution of skin lesions [Figure 2].

Cryoglobulinemic vasculitis develops in approximately 15% patients with HCV infection, while circulating cryoglobulins are detected in 40–60% of the patients.<sup>[1]</sup> Viral clearance is important for the treatment of vasculitis as clinical remission is closely linked with viral clearance. Pegylated interferon  $\alpha$  with ribavirin with or without rituximab is the standard of care for the management of cryoglobulinemic vasculitis, but 30–40% patients do not respond to this combination.<sup>[2]</sup> With the availability of direct-acting antiviral agents, treatment of this condition has changed dramatically.<sup>[3]</sup> In an open label multicentre study, sofosbuvir 400 mg per day and daclatasvir 60 mg per day for 12 weeks resulted in complete clinical response in 90% patients.<sup>[4]</sup>

### Financial support and sponsorship

Nil.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com



Figure 1: Gangrene involving the left great toe



Figure 2: Complete resolution of the gangrene with post-inflammatory pigmentation on the left great toe after 12 weeks

### Conflicts of interest

There are no conflicts of interest.

### References

1. Cooley JE, Papadimitriou JC, Kauffman CL. Hepatitis C-associated cryoglobulinemia. *Cutis* 1995;56:324-8.
2. Misiani R, Bellavita P, Fenili D, Vicari O, Marchesi D, Sironi PL, *et al.* Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. *N Engl J Med* 1994;330:751-6.
3. Welsch C, Jesudian A, Zeuzem S, Jacobson I. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. *Gut* 2012;61(Suppl 1):i36-46.
4. Saadoun D, Pol S, Ferfar Y, Alric L, Hezode C, Si Ahmed SN, *et al.* Efficacy and Safety of Sofosbuvir Plus Daclatasvir for Treatment of HCV-Associated Cryoglobulinemia Vasculitis. *Gastroenterology* 2017;153:49-52.

Shekhar Neema,  
D. Banerjee,  
S. K. Pramanik

Department of Dermatology,  
Gastroenterology and  
Hematology, Command  
Hospital, Kolkata, West Bengal,  
India

### Address for correspondence:

Dr. Shekhar Neema,  
Department of Dermatology,  
Gastroenterology and  
Hematology, Command  
Hospital, Kolkata,  
West Bengal, India.  
E-mail: Shekharadvait@gmail.  
com

### Access this article online

Website: www.idoj.in

DOI: 10.4103/idoj.IDOJ\_176\_17

### Quick Response Code:



**How to cite this article:** Neema S, Banerjee D, Pramanik SK. Through the lens: Cryoglobulinemia. *Indian Dermatol Online J* 2018;9:135.

**Received:** June, 2017. **Accepted:** July, 2017.